Using living systems to guide the design and assembly of better medicines, Think Bioscience is described as re-imagining synthetic biology -- developing small-molecule therapeutics that target difficult-to-drug proteins. Spun-out of CU Boulder and a client company of Innosphere Ventures' incubation program, Think Bioscience is structured around combining applied microbiology, enzymology and data science to develop small-molecule therapeutics against challenging targets. Taking a somewhat different approach to drug discovery, the firm is combining applied microbiology, enzymology, and computational science to develop small-molecule therapeutics against elusive targets. The proof-of-concept work previously tackled had demonstrated a novel inhibitor against PTP1B, a well-validated âundruggableâ target. PTP1B is implicated in HER2+ breast cancer, diabetes, and obesity: results published in ACS Synthetic Biology in May 2021. With labs in the Porter Biosciences building on campus,Think Bioscience has an exclusive license to the foundational
